| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate |
2014-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_533e38e46bd680d718f740a25f5ff8cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61526d021b343643b0b213ebf4533cbc |
| publicationDate |
2015-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201532613-A |
| titleOfInvention |
Combination therapy for neoplasia (NEOPLASIA) treatment |
| abstract |
The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for the treatment of prostate tumors, including benign prostatic hyperplasia (BPH), prostate cancer and especially CRPC, wherein the antagonist and the androgen receptor antagonist Used in combination. An embodiment of the invention is wherein the androgen receptor antagonist is enzalutamide. |
| priorityDate |
2013-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |